%0
Generic
%T
Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC): An interim analysis of the CEBIFOX trial.
%A Kasper, Stefan
%A Meiler, Johannes
%A Knipp, Heike
%A Hoehler, Thomas
%A Reimer, Peter
%A Steinmetz, Tilman
%A Berger, Winfried
%A Linden, Gabriele
%A Ting, Saskia
%A Markus, Peter
%A Paul, Andreas
%A Schuler, Martin H.
%A Trarbach, Tanja
%I American Society of Clinical Oncology (ASCO)
%@ 0732-183X
%@ 1527-7755
%K Cancer Research
%K Oncology
%D 2013
%C American Society of Clinical Oncology (ASCO)
%U http://slubdd.de/katalog?TN_libero_mab2